Physician profile
Daniel Swartz
NPI 1831134899
$83,338.00
in general payments reported to CMS, 2019-2025
23 companies · $486 in 2025
The $486 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $640 · 2021: $748 · 2022: $40K · 2023: $9,892 · 2024: $11K · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,500 · Food and Beverage: $3,274 · Travel and Lodging: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $12,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,500.00 |
| Food and Beverage | $3,274.31 |
| Travel and Lodging | $181.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $80,597.00 | 2019-2025 | |
| Teleflex LLC | $381.37 | 2024-2025 | Titan Sgs Bailout Chuck, Titan Sgs |
| Inspire Medical Systems, INC. | $376.34 | 2022-2024 | Inspire |
| Tela Bio, INC. | $330.43 | 2019-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Lilly USA, LLC | $247.80 | 2024 | Mounjaro, Zepbound |
| Ethicon US, LLC | $229.18 | 2019-2021 | |
| Davol INC. | $172.00 | 2022 | |
| Medtronic, INC. | $168.23 | 2022 | |
| Covidien Lp | $126.32 | 2019 | |
| Novo Nordisk INC | $95.15 | 2024-2025 | Wegovy |
| Karl Storz Endoscopy-America | $90.74 | 2019 | |
| Atricure, INC. | $85.85 | 2025 | Atriclip Laa Exclusion System, Synergy Ablation System |
| Edwards Lifesciences Corporation | $81.34 | 2019 | |
| Abbvie INC. | $70.37 | 2019-2024 | |
| Endo Pharmaceuticals INC. | $69.83 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $45.58 | 2025 | Voquezna |
| Becton, Dickinson and Company | $39.66 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $31.09 | 2024-2025 | |
| Ambu INC. | $25.00 | 2021 | |
| Abbott Laboratories | $24.12 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.73 | 2022 | |
| Braintree Laboratories, INC. | $15.59 | 2020 | |
| Kls-Martin L.P. | $14.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Swartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.